

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

**CHANGE IN COMPOSITION OF
THE NOMINATION COMMITTEE**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) hereby announces that the following changes were approved with effect from March 31, 2025:

- (i) Mr. Li Li, chairman of the Board and an executive Director, ceased to be a member of the nomination committee of the Board (the “**Nomination Committee**”); and
- (ii) Ms. Li Tan, an executive Director and deputy general manager, has been appointed as a member of the Nomination Committee.

By Order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
March 31, 2025

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.